Filing Flows

Filing Flows › Dogwood Therapeutics (DWTX) › Next earnings date

Dogwood Therapeutics (DWTX) earnings: beat the estimate

Dogwood Therapeutics (DWTX) reported on Nov 5, 2026 and beat the EPS estimate: −$0.14 against −$0.15 (+9.7%). Revenue was $100K for Q3 2026. It beat the EPS estimate in 75% of the quarters on record.

Last result+9.7% vs estimate
Beat rate75%

The last report

Dogwood Therapeutics reported revenue of $100K for the third quarter 2026, net loss $4.9M. How it makes money → · Every quarter →

Dogwood Therapeutics: EPS against the estimate, last 4 reportsDogwood Therapeutics: EPS against the estimate, last 4 reportsEstimateReported−$0.86−$0.26Mar 26−$0.20−$0.15May 26−$0.14−$0.34Aug 26−$0.15−$0.14Nov 26
Latest (Nov 26): Estimate −$0.15, Reported −$0.14.

Dogwood Therapeutics' latest quarter

Dogwood Therapeutics, Q3 2026: revenue $100K, net loss $4.9M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.

Questions

Did Dogwood Therapeutics beat earnings?

Dogwood Therapeutics (DWTX) reported on Nov 5, 2026 and beat the EPS estimate: −$0.14 against −$0.15 (+9.7%).

When does DWTX report earnings?

The next date is not set yet.

Does Dogwood Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 75% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.